AMRS Stock Overview
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty markets through its consumer brands and as a supplier of sustainable and natural ingredients in Europe, the United States, Asia, Brazil, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$6.78|
|52 Week High||US$23.42|
|52 Week Low||US$2.56|
|1 Month Change||-54.34%|
|3 Month Change||-57.76%|
|1 Year Change||132.19%|
|3 Year Change||37.25%|
|5 Year Change||-46.17%|
|Change since IPO||-97.26%|
Recent News & Updates
Amyris Buying Opportunity Created By Q3 Miss, Mega Convert And Potential Revolutionary COVID Vaccine
Big Revenue miss for Q3 due to supply chain shortages and Amyris guides lower for Q4. Surprise $690 million convert is less dilutive (12%, not 18%) and at a beneficially higher effective conversion price ($15.90, not $10.75/share) due to a capped call hedge. Mega overfunding adds about $590 million cash which can be used to pay off debt, finance new plants, acquire IP and assets and allow Amyris to negotiate deals from strength. Potential revolutionary COVID vaccine in 50/50 Joint Venture with ImmunityBio - Clinical trial data in Q1 2022, with an objective of up to 1 billion doses in 2022. Potentially great buying opportunity especially for those that missed the stock a year ago as delays from supply chain shortages and effects of the surprise convert should be temporary.
Amyris: Assessing Financial Capacity To Sustain Organic Growth, Carry COVID Research And Pay For Acquisition
Amyris, a synthetic clean health and beauty biology company, is a key supplier of sustainable and natural ingredients and possesses some strong consumer brands too. Lack of market enthusiasm following the MG Empower deal points to investors having some doubts about financial capacity in view of the amount of cash in the balance sheet. Also, the company has a collaboration for COVID vaccine development implying expenses for clinical trials. The company has used equity financing for acquisitions of brands before, but, for this one, it will probably require an equity offering exercise. Still, experiencing robust organic growth in consumer and ingredients, with some advantageous COVID collaborations and considering the revenue and cost synergies, the stock is a buy.
|AMRS||US Chemicals||US Market|
Return vs Industry: AMRS exceeded the US Chemicals industry which returned 19.9% over the past year.
Return vs Market: AMRS exceeded the US Market which returned 21.3% over the past year.
|AMRS Average Weekly Movement||13.3%|
|Chemicals Industry Average Movement||5.2%|
|Market Average Movement||6.0%|
|10% most volatile stocks in US Market||15.0%|
|10% least volatile stocks in US Market||2.3%|
Stable Share Price: AMRS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: AMRS's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty markets through its consumer brands and as a supplier of sustainable and natural ingredients in Europe, the United States, Asia, Brazil, and internationally. It manufactures and sells products for the health and wellness, clean beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks.
Amyris Fundamentals Summary
|AMRS fundamental statistics|
Is AMRS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AMRS income statement (TTM)|
|Cost of Revenue||US$208.20m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.35|
|Net Profit Margin||-116.91%|
How did AMRS perform over the long term?See historical performance and comparison
Is Amyris undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AMRS ($6.78) is trading below our estimate of fair value ($47.36)
Significantly Below Fair Value: AMRS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AMRS is unprofitable, so we can't compare its PE Ratio to the US Chemicals industry average.
PE vs Market: AMRS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AMRS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AMRS has negative assets, so we can't compare its PB Ratio to the US Chemicals industry average.
How is Amyris forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMRS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: AMRS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AMRS's is expected to become profitable in the next 3 years.
Revenue vs Market: AMRS's revenue (27.9% per year) is forecast to grow faster than the US market (10.1% per year).
High Growth Revenue: AMRS's revenue (27.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AMRS's Return on Equity is forecast to be high in 3 years time
How has Amyris performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AMRS is currently unprofitable.
Growing Profit Margin: AMRS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AMRS is unprofitable, and losses have increased over the past 5 years at a rate of 27.8% per year.
Accelerating Growth: Unable to compare AMRS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AMRS is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (24.1%).
Return on Equity
High ROE: AMRS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Amyris's financial position?
Financial Position Analysis
Short Term Liabilities: AMRS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: AMRS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: AMRS has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: AMRS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AMRS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AMRS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.4% each year
What is Amyris's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AMRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AMRS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AMRS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AMRS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AMRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Melo (55 yo)
Mr. John G. Melo has been the Chief Executive Officer and Director at Amyris, Inc. since January 2007 and has been its President since June 2008. As President and Chief Executive Officer, Mr. Melo has led...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD1.34M) is below average for companies of similar size in the US market ($USD3.64M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
Experienced Management: AMRS's management team is considered experienced (4.2 years average tenure).
Experienced Board: AMRS's board of directors are considered experienced (3.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AMRS insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.9%.
Amyris, Inc.'s employee growth, exchange listings and data sources
- Name: Amyris, Inc.
- Ticker: AMRS
- Exchange: NasdaqGS
- Founded: 2003
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: US$2.090b
- Shares outstanding: 308.24m
- Website: https://www.amyris.com
Number of Employees
- Amyris, Inc.
- 5885 Hollis Street
- Suite 100
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/27 23:01|
|End of Day Share Price||2021/11/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.